Compare Apple Inc (AAPL) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apple Inc vs Revvity Inc — how do they compare? Apple Inc trades at $303.37 (market cap $4.41T), while Revvity Inc trades at $117.12 (market cap $13.15B). The key difference: Apple Inc is far larger — about 335.4× Revvity Inc's market cap, and Apple Inc pays the higher dividend (0.36%). Which is the better fit depends on your goals.
| AAPL | RVTY | |
|---|---|---|
Market Cap | $4.41T | $13.15B |
Volume | 100,358,844 | — |
Sector | Technology | Technology |
52-Week High | $340.08 | $117.88 |
52-Week Low | $224.90 | $82.26 |
Enterprise Value | $4.43T | $15.47B |
Dividend Yield | 0.36% | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apple (AAPL) trades at $305.75, up 0.28% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong Q2 2026 EPS of $2.02 versus $1.89 expected, continuing a pattern of exceeding expectations. Revenue grew to $416.16B in 2025 with net income margin expanding to 26.91%. Analyst consensus remains positive with a $335.29 price target, though technical indicators show selling pressure with support at $300.
Apple's massive installed base of 2.5 billion devices provides significant AI opportunity, but faces headwinds from potential Q3 earnings miss and union disputes. The stock trades at premium valuations (P/E 34.66) but maintains strong cash flow generation. Upside potential exists if AI partnerships drive growth, while risks include smartphone market saturation and regulatory pressures.
RVTY trades at $117.88, up 1.6% today, with a bullish technical outlook and strong earnings momentum after beating Q2 2026 EPS estimates. The stock is near the consensus price target of $120.50, supported by a 51.72% analyst buy rating. Recent news highlights product launches like the SuperFlex prenatal system and investor conference participation, reinforcing growth prospects in diagnostics and biotech tools.
The outlook remains positive with revenue stability and margin strength, but elevated P/E of 55.64 poses valuation risk. Key opportunities include diagnostic demand and AI-driven workflows, while risks involve competitive pressures and execution challenges. Net cash flow turned positive in 2026, signaling improved financial health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
